• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Amgen "Clears First Regulatory Hurdle for Biosimilar Production"

Article

February 02, 2016.

FDA News reports that Amgen "has cleared its first regulatory hurdle for biosimilar production with the FDA’s acceptance of its Biologics License Application (BLA) for a biosimilar of the immunosuppressant Humira".

ABP 501 is the first of the company’s potential biosimilars that has made it this far, with two others currently undergoing trials. The BLA was submitted to the FDA in November following successful Phase 3 trials that “met their primary endpoints showing clinical equivalence” to AbbVie’s Humira, the company said.

 

Related Videos
Related Content
UniDoc

UniDoc Brings AI-Powered Health Cube to Alaska

April 17th 2024
Article

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Riccardo Butta

At-Home Patients and AI: Q&A with Riccardo Butta

April 16th 2024
Article

Butta discusses how new technologies are being implemented in at-home devices.

Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Dan Milczarski, Executive Vice President of Process and Technology, CQfluency.

All in on AI is Not the Solution in Life Sciences and Health Care

March 13th 2024
Article

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.